文献速递妇科

BET抑制剂INCB054329降低同源重组效率并增强PARP抑制剂在卵巢癌中的活性

The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2018-03-20

该研究以同源重组(HR)功能正常的卵巢癌细胞系及SKOV-3和患者来源异种移植瘤为对象,检测BRD4靶向siRNA、新型BET抑制剂(INCB054329、INCB057643)及已知BET抑制剂JQ1与PARP抑制剂(奥拉帕利、芦卡帕利)联用效果。结果显示BET抑制剂降低BRCA1和RAD51表达与功能、降低HR报告活性,并增敏奥拉帕利诱导的生长抑制、DNA损伤与凋亡,所有测试BET抑制剂与PARP抑制剂均显示协同作用。

要点

  • BET抑制剂或BRD4 siRNA降低BRCA1和RAD51表达与功能,降低HR报告活性。
  • BET抑制剂增敏卵巢癌细胞对奥拉帕利诱导的生长抑制、DNA损伤和凋亡。
  • 所有测试BET抑制剂与PARP抑制剂联用均观察到协同作用。

核心结论

  • 作者认为结果提供了强有力依据,支持使用BET抑制剂将PARP抑制剂的疗效扩展至HR功能正常的卵巢肿瘤,并可能使大量被诊断为此类难治性疾病的女性获益。

研究设计与样本

  • 体外研究使用HR功能正常的卵巢癌细胞系OVCAR-3、OVCAR-4、SKOV-3和UWB1.289+BRCA1,分别以BRD4靶向siRNA、新型BET抑制剂INCB054329和INCB057643、已知BET抑制剂JQ1及PARP抑制剂奥拉帕利和芦卡帕利处理。
  • 体内研究使用SKOV-3和卵巢癌患者来源异种移植瘤模型评估肿瘤生长。
  • 细胞生长与活力采用磺酰罗丹明B法检测,DNA损伤与修复、凋亡和增殖标志物采用免疫荧光和蛋白质印迹评估。

主要发现

  • 在培养细胞中,BRD4 siRNA或INCB054329降低BRCA1和RAD51的表达与功能,降低HR报告活性,并增敏奥拉帕利诱导的生长抑制、DNA损伤诱导和凋亡。
  • 所有测试的BET抑制剂与PARP抑制剂之间均观察到协同作用。
  • INCB054329与奥拉帕利协同抑制异种移植瘤生长,伴BRCA1表达和增殖降低、凋亡和DNA损伤增加。

临床怎么用

  • 原文结论未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Homologous recombination (HR)-proficient ovarian tumors have poorer clinical outcomes and show resistance to poly ADP ribose polymerase inhibitors (PARPi). A subset of HR-proficient ovarian tumors show amplification in bromodomain and extra-terminal (BET) genes such as BRD4. We aimed to test the hypothesis that BRD4 inhibition sensitizes ovarian cancer cells to PARPi by reducing HR efficiency and increasing DNA damage. METHODS: HR-proficient ovarian cancer cell lines (OVCAR-3, OVCAR-4, SKOV-3, UWB1.289+BRCA1) were treated with BRD4-targeting siRNA, novel (INB054329, INCB057643) and established (JQ1) BET inhibitors (BETi) and PARPi (olaparib, rucaparib). Cell growth and viability were assessed by sulforhodamine B assays in vitro, and in SKOV-3 and ovarian cancer patient-derived xenografts in vivo. DNA damage and repair (pH2AX, RAD51 and BRCA1 foci formation, and DRGFP HR reporter activity), apoptosis markers (cleaved PARP, cleaved caspase-3, Bax) and proliferation markers (PCNA, Ki67) were assessed by immunofluorescence and western blot. RESULTS: In cultured cells, inhibition of BRD4 by siRNA or INCB054329 reduced expression and function of BRCA1 and RAD51, reduced HR reporter activity, and sensitized the cells to olaparib-induced growth inhibition, DNA damage induction and apoptosis. Synergy was observed between all BETi tested and PARPi. INCB054329 and olaparib also co-operatively inhibited xenograft tumor growth, accompanied by reduced BRCA1 expression and proliferation, and increased apoptosis and DNA damage. CONCLUSIONS: These results provide strong rationale for using BETi to extend therapeutic efficacy of PARPi to HR-proficient ovarian tumors and could benefit a substantial number of women diagnosed with this devastating disease.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Wilson AJ, Stubbs M, Liu P, et al. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer. Gynecol Oncol. 2018. PMID: 29567272. doi:10.1016/j.ygyno.2018.03.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。